Evidence map›Paper›PMID 39081249›Full record

ArticleJournal of the Royal Society, Interface2024

Computational modelling of scleral photocrosslinking: from rat to minipig to human.

Amy J Wood-Yang, Brandon G Gerberich, Mark R Prausnitz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Royal Society, Interface, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amy J Wood-YangSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.ORCID 0000-0002-6219-8927
Brandon G GerberichWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
Mark R PrausnitzSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.

Funding

Targeting Scleral Stiffness as a Novel Therapeutic Approach in GlaucomaR01EY025286 · NEI · GEORGIA INSTITUTE OF TECHNOLOGY · PI ETHIER, C ROSS · 2015 to 2019
$2.5M
National Science Foundation Graduate Research Fellowship ProgramNEI NIH HHS R01 EY025286NIH HHS
6 · The paper itself

Abstract

Selective scleral crosslinking has been proposed as a novel treatment to increase scleral stiffness to counteract biomechanical changes associated with glaucoma and high myopia. Scleral stiffening has been shown by transpupillary peripapillary scleral photocrosslinking in rats, where the photosensitizer, methylene blue (MB), was injected retrobulbarly and red light initiated crosslinking reactions with collagen. Here, we adapted a computational model previously developed to model this treatment in rat eyes to additionally model MB photocrosslinking in minipigs and humans. Increased tissue length and subsequent diffusion and light penetration limitations were found to be barriers to achieving the same extent of crosslinking as in rats. Per cent inspired O

Indexed as

ScleraSwine, MiniatureAnimalsCollagenComputer SimulationCross-Linking ReagentsHumansMethylene BlueModels, BiologicalPhotosensitizing AgentsRatsSwineCollagenCross-Linking ReagentsMethylene BluePhotosensitizing Agentscomputational modellingglaucomaocular drug deliveryphotosensitizerscleral photocrosslinking

Identifiers

PMID39081249
PMCPMC11289678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.